Co-Diagnostics, Inc.

Co-Diagnostics, Inc. has entered into a material transfer agreement with ReadyGo Diagnostics Ltd to assess the compatibility of ReadyGo's sample collection and preparation technologies with Co-Diagnostics' Co-Dx PCR platform. ReadyGo will supply its sampling materials for evaluation, aiming to enhance the Co-Dx PCR platform's usability in decentralized testing environments. This preliminary evaluation does not guarantee any future commercial agreements between the two companies.

Co-Diagnostics, Inc. reported a net loss of $6.28 million for the second quarter of 2026 and $15.42 million for the first half of 2026. The company's cash and cash equivalents significantly decreased to $3.65 million by June 30, 2026, from $11.88 million at year-end 2025. Management has concluded that substantial doubt exists about the company's ability to continue as a going concern, dependent on obtaining additional financing and achieving operational efficiencies.

Co-Diagnostics, Inc. reported its second quarter 2026 financial results, with revenue increasing slightly to $0.17 million and net loss improving to $6.3 million, or $1.46 per share, compared to the prior year. The company also announced significant operational progress, including the submission of its FDA 510(k) application for the Co-Dx PCR Flu A/B & RSV test and a $3.0 million private placement. Strategic advancements were made in manufacturing, global commercialization, and product pipeline development.

Co-Diagnostics, Inc. entered into an inducement agreement with certain warrant holders to exercise existing warrants for 1,702,362 shares at $1.571 per share, generating approximately $2.67 million in gross proceeds. In consideration, the company will issue new common stock purchase warrants for up to 3,404,724 shares at an exercise price of $1.56, contingent on stockholder approval. Maxim Group LLC will serve as the exclusive placement agent, receiving a 7.0% cash fee and $50,000 for expenses. The net proceeds are intended for general corporate purposes.

Co-Diagnostics, Inc. amended its Equity Distribution Agreement with Maxim Group LLC, removing the fixed aggregate dollar limitation on sales of its common stock. This change allows the company to sell shares up to the amount registered under its effective shelf registration statement. Additionally, the company agreed to extend a non-issuance period with existing investors until August 14, 2026.

Co-Diagnostics, Inc. entered into a private placement transaction to raise $3.0 million in gross proceeds, before deducting fees and expenses. The company intends to use the net proceeds for general corporate purposes and working capital. As part of the private placement, Co-Diagnostics agreed to issue 54,915 shares of common stock, pre-funded warrants to purchase 1,592,532 shares of common stock, and common warrants to purchase 3,294,894 shares of common stock. Maxim Group LLC acted as the exclusive placement agent for the transaction, which is expected to close on May 21, 2026.

Co-Diagnostics, Inc. reported a net loss of $9.14 million for Q1 2026, an increase from $7.53 million in Q1 2025. The company's management has concluded that substantial doubt exists about its ability to continue as a going concern for the next 12 months, citing dependence on future financing and profitable operations. Despite a significant increase in product revenue to $145,954, operating expenses also rose, leading to a larger loss from operations. The company raised $4.33 million through an at-the-market offering to support its capital requirements.

Co-Diagnostics reported its first quarter 2026 financial results, with revenue increasing to $0.15 million from $0.05 million year-over-year. However, the company posted a net loss of $9.1 million, up from $7.5 million in Q1 2025, primarily due to higher operating expenses driven by research and development. Despite the increased loss, Co-Diagnostics highlighted significant operational progress, including receiving a CDSCO license and ISO 13485 certification for its Indian operations, expanding CoSara's distribution across South Asia, and initiating clinical studies for its TB program. The company also completed enrollment for its upper respiratory multiplex test clinical studies and expanded its international presence and intellectual property.